Stock Research: Laurus Labs

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Laurus Labs

BSE:540222 INE947Q01028
1
  • Value
    4
  • Growth
    91
  • Safety
    Safety
    3
  • Combined
    1
  • Sentiment
    30
  • 360° View
    360° View
    1
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Laurus Labs Limited is an India-based pharmaceutical and biotechnology company. It operates in Generics API, Generics FDF, CDMO custom synthesis (Laurus Synthesis), and Biotechnology (Laurus Bio), serving global pharmaceutical, crop science, animal health, regenerative medicine, vaccines, and cultured meat sectors. In the last fiscal year, the company had a market cap of $5164 millions, profits of $315 millions, revenue of $650 millions, and 6167 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 1 (better than 1% compared with alternatives), overall professional sentiment and financial characteristics for the stock Laurus Labs are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for Laurus Labs. The consolidated Growth Rank has a good rank of 91, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. It ranks higher than 91% of competitors in the same industry. The other indicators are below average, namely the Value, Safety, and Sentiment Ranks.The Value Rank at 3 means that the share price of Laurus Labs is on the high side compared with its peers regarding revenues, profits, and invested capital. The stock price is higher than for 97% of alternative stocks in the same industry. The consolidated Safety Rank has a riskier rank of 4, which means that the company has a riskier financing structure than 96% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. The consolidated Sentiment Rank also has a low rank of 30, indicating professional investors are more pessimistic about the stock than for 70% of alternative investment opportunities. ...read more

more
Index
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 10-Sep-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
3 15 27 47
Growth
91 97 19 65
Safety
Safety
4 3 9 9
Sentiment
30 57 14 42
360° View
360° View
1 31 1 25
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
5 3 24 9
Opinions Change
50 81 50 22
Pro Holdings
n/a 43 15 90
Market Pulse
61 56 38 61
Sentiment
30 57 14 42
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
3 15 27 47
Growth
91 97 19 65
Safety Safety
4 3 9 9
Combined
1 19 1 17
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
1 5 15 63
Price vs. Earnings (P/E)
25 46 55 52
Price vs. Book (P/B)
15 28 49 37
Dividend Yield
8 12 15 28
Value
3 15 27 47
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
92 84 78 89
Profit Growth
92 90 4 12
Capital Growth
17 59 9 67
Stock Returns
100 95 39 65
Growth
91 97 19 65
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
11 20 26 22
Refinancing
10 12 18 14
Liquidity
17 16 30 45
Safety Safety
4 3 9 9

Similar Stocks

Discover high‑ranked alternatives to Laurus Labs and broaden your portfolio horizons.

Kalbe Farma

IDX:KLBF
Country: Indonesia
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

NMDC

BSE:526371
Country: India
Industry: Steel
Size: Medium
Full Stock Analysis

Maruti Suzuki

NSEI:MARUTI
Country: India
Industry: Automobile Manufacturers
Size: Large
Full Stock Analysis

Cipla

NSEI:CIPLA
Country: India
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.